Shilpa Medicare Share Price

NSE: SHILPAMED

₹ 606.20

+₹2.60 (0.43%)

Last updated 24 Jul, 2026, 15:40 IST

Shilpa Medicare Share Price Today

As of 25 Jul 2026, Shilpa Medicare share price is ₹606.20. The stock opened at ₹601.00, compared to its previous close of ₹603.60. During today's trading session, Shilpa Medicare share price moved in the range of ₹597.50 to ₹614.45, with an average price of ₹605.98 for the day. Looking at its last 52-week, the stock has touched a low of ₹259.50 and a high of ₹650.00. On the performance front, Shilpa Medicare share price has increased by 127.04% over the last six months and is up 34.34% on a year-on-year basis.

₹597.50

0.43% up today

₹614.45

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 97.93% QoQ

Latest Earning

Net Profit TrendUp by 141.79% QoQ

Latest Earning

Revenue TrendUp by 6.85% QoQ

Stock Performance

OutperformingBeat Nifty by 1.92 % in last 1 month

Shareholding Pattern

DIIDII increased stake by 11.89%

Shareholding Pattern

FIIFII increased stake by 2.76%

Shilpa Medicare Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹6,66,007+₹1,66,007 (+33.20%)

3 Year

₹17,05,684+₹12,05,684 (+241.14%)

5 Year

₹9,60,241+₹4,60,241 (+92.05%)

₹482.90₹724.30

Circuit Low

Circuit High

₹259.50₹650.00

52-Week Low

52-Week High

Circuit

₹482.90

₹724.30

52-week

₹259.50

₹650.00

Mkt Cap Cr

11,796.50

P/E

48.48

P/B

4.55

ROE

9.39%

D/E

0.05

ROCE

10.73%

Div. Yield

0.10%

EPS(TTM)

6.80

Turnover

0.22

EV/EBITDA

26.62

Net Margin

0.00%

Op. Margin

0.00%

ROA

6.57%

Quick Ratio

0.00

Curr. Ratio

3.29

Mkt Cap Cr

11,796.50

P/E

48.48

P/B

4.55

ROE

9.39%

D/E

0.05

ROCE

10.73%

Div. Yield

0.10%

EPS(TTM)

6.80

Turnover

0.22

EV/EBITDA

26.62

Net Margin

0.00%

Op. Margin

0.00%

ROA

6.57%

Quick Ratio

0.00

Curr. Ratio

3.29

Based on fundamentals, this stock's

Performance

Excellent

Shilpa Medicare outperforming all market indices

Valuation

Overvalued

Shilpa Medicare appears overvalued compared to its peers

Earnings

Excellent

Shilpa Medicare revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	96,204.70	30.22	2.53	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.40	16.70%	97.21	0.12%	0.64	13.72

Shilpa Medicare Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹1,286.41	₹1,151.60	₹1,050.11	₹1,145.52
Other Income	₹23.15	₹8.17	₹17.40	₹14.25
Total Revenue	₹1,309.57	₹1,159.77	₹1,067.51	₹1,159.77
Total Expenses	₹1,157.89	₹1,106.79	₹1,101.98	₹1,062.63
Profit Before Tax	₹122.33	₹54.34	-₹38.28	₹102.26
Tax	₹44.04	₹22.39	-₹7.31	₹41.68
Profit After Tax	₹78.30	₹31.96	-₹30.97	₹60.58
EPS - Basic	₹8.04	₹3.67	-₹3.75	₹7.26
EPS - Diluted	₹8.04	₹3.67	-₹3.75	₹7.26

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	₹122.33	₹54.34	-₹38.28	₹102.26
Income before WC changes	₹317.38	₹275.78	₹109.53	₹211.61
Change in Assets	-₹122.76	-₹125.72	₹107.29	-₹186.98
Change in Liabilities	-₹15.41	₹27.80	-₹4.52	₹114.99
Change in WC	-₹138.18	-₹97.92	₹102.77	-₹71.99
Cash flow from Operations	₹132.18	₹136.67	₹179.92	₹105.13
Cash flow from Investing	-₹199.08	-₹166.58	-₹232.61	-₹285.50
Cash flow from Financing	₹62.65	₹46.78	₹45.80	₹82.86
Total Cash Flow	-₹4.25	₹16.86	-₹6.89	-₹97.51
Cash (Start of the year)	₹31.76	₹19.07	₹25.62	₹122.85
Cash (End of the year)	₹28.52	₹31.76	₹19.07	₹25.34

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹2,325.04	₹2,216.38	₹2,134.37	₹1,988.30
Current Assets	₹985.67	₹876.83	₹769.55	₹887.19
Total Assets	₹3,310.71	₹3,093.20	₹2,903.93	₹2,875.50
Current Liabilities	₹674.23	₹693.35	₹784.45	₹611.54
Net Current Asset	₹311.44	₹183.48	-₹14.89	₹275.66
Non-Current Liabilities	₹272.77	₹599.90	₹345.12	₹452.82
Equity Capital	₹2,363.70	₹1,799.96	₹1,774.36	₹1,811.15
Total Equity & Liabilities	₹3,310.71	₹3,093.20	₹2,903.93	₹2,875.50

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹477.34	₹309.79	₹247.70	₹356.95
Other Income	₹83.83	₹89.12	₹68.64	₹40.86
Total Revenue	₹561.18	₹398.90	₹316.35	₹397.81
Total Expenses	₹408.20	₹350.36	₹359.08	₹379.14
Profit Before Tax	₹107.24	₹38.09	-₹58.28	₹27.49
Tax	₹37.43	₹11.15	-₹8.79	₹7.33
Profit After Tax	₹69.80	₹26.94	-₹49.48	₹20.16
EPS - Basic	₹7.16	₹3.10	₹6.59	₹16.87
EPS - Diluted	₹7.16	₹3.10	₹6.59	₹16.87

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	₹107.24	₹38.09	₹12.68	₹192.89
Income before WC changes	₹114.49	₹55.22	-₹22.88	₹225.53
Change in Assets	-₹148.47	-₹64.71	₹21.21	-₹113.72
Change in Liabilities	₹32.29	₹25.99	₹12.16	₹96.55
Change in WC	-₹116.18	-₹38.72	₹33.37	-₹17.17
Cash flow from Operations	-₹19.06	₹9.55	₹2.08	₹173.87
Cash flow from Investing	-₹433.29	₹155.82	-₹94.83	-₹378.97
Cash flow from Financing	₹450.09	-₹163.07	₹87.68	₹97.23
Total Cash Flow	-₹2.26	₹2.30	-₹5.07	-₹107.88
Cash (Start of the year)	₹4.46	₹2.49	₹7.42	₹115.01
Cash (End of the year)	₹4.42	₹4.46	₹2.35	₹7.13

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹2,529.38	₹2,041.66	₹1,882.41	₹2,586.68
Current Assets	₹477.29	₹376.97	₹636.25	₹309.44
Total Assets	₹3,006.66	₹2,418.62	₹2,518.66	₹2,896.12
Current Liabilities	₹226.89	₹212.64	₹242.71	₹161.65
Net Current Asset	₹250.40	₹164.33	₹393.54	₹147.79
Non-Current Liabilities	₹79.18	₹63.27	₹158.37	₹668.80
Equity Capital	₹2,700.59	₹2,142.72	₹2,117.58	₹2,065.67
Total Equity & Liabilities	₹3,006.66	₹2,418.62	₹2,518.66	₹2,896.12

* All values are in INR Crore

Qty

Bid

Ask

Qty

606.2

2576

Bid Total: 0

Ask Total: 2576

Buy orders: 0%

Sell orders: 100%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

52.98

Neutral

ATR (14)

22.11

Neutral

STOCH(9,6)

16.57

Bullish

STOCH RSI (14)

4.2

Bullish

ADX(9)

37.81

Bearish

UO(9)

42.5

Neutral

ROC(12)

1.82

Bullish

WillR(14)

-70.76

Neutral

Period

Simple value

Exponential vaue

620.53

618.12

10D

626.79

619

20D

610.31

606.95

50D

555.73

557.22

100D

465.51

496.32

About Shilpa Medicare

ISIN

INE790G01031

Sector Market Cap

₹ 11,796.5 Cr

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.

Shilpa Medicare Financial Highlights

Revenue: Shilpa Medicare reported revenue of ₹1,548.71 crore in FY26 vs ₹1,309.76 crore in FY25. It showed an increase of 18.24% on a yearly basis.
Operating Profit: Shilpa Medicare reported an operating profit of ₹295.31 crore in FY26 vs ₹122.33 crore in FY25. It showed an increase of 141.40% on a year-on-year basis.
Net Profit: Shilpa Medicare reported a net profit of ₹243.33 crore in FY26 vs ₹78.29 crore in FY25. It showed an increase of 210.81% on a yearly basis.

Shilpa Medicare Quarterly Result Highlights

Shilpa Medicare reported revenue of ₹438.66 crore in Mar 2026, compared with ₹410.54 crore in Dec 2025, representing an increase of 6.85% on a quarter-on-quarter (QoQ) basis.
Shilpa Medicare reported an operating profit of ₹120.44 crore in Mar 2026, compared with ₹60.85 crore in Dec 2025, representing an increase of 97.93% on a quarter-on-quarter (QoQ) basis.
Shilpa Medicare reported a profit of ₹107.79 crore in Mar 2026, compared with ₹44.58 crore in Dec 2025, reflecting an increase of 141.79% on a QoQ basis.
The earnings per share (EPS) of Shilpa Medicare stood at ₹8.04 during Mar 2026.